Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $582,198.40 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $261.09 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $268.21. The firm has a market cap of $11.58 billion, a price-to-earnings ratio of 12.34 and a beta of 0.54. The business’s fifty day moving average is $239.06 and its 200 day moving average is $230.10.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period in the previous year, the company posted $4.86 EPS. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. Research analysts predict that United Therapeutics Co. will post 23.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on UTHR shares. The Goldman Sachs Group upped their price target on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company upped their price target on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $308.78.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Rise Advisors LLC bought a new position in United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC bought a new position in United Therapeutics in the 4th quarter worth about $43,000. Benjamin F. Edwards & Company Inc. increased its stake in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. bought a new position in United Therapeutics in the 3rd quarter worth about $91,000. Finally, Janiczek Wealth Management LLC increased its stake in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.